Table 1.

Baseline characteristics of patients with FM (n = 75).

	Mg (n = 37)	Placebo (n = 38)
Age (years, mean ± SD)	54.0 ± 11.5	51.8 ± 10.9
BMI (mean ± SD)	25.7 ± 5.1	26.5 ± 6.1
FM duration (years, mean ± SD)	9.6 ± 7.1	7.8 ± 6.2
Widespread Pain Index, ACR 2016 (0–19) (mean ± SD)	12.3 ± 3.1	12.8 ± 3.2
SSS, ACR 2016 (0–12) (mean ± SD)	8.6 ± 1.5	8.8 ± 1.8
DASS-42 stress score (0–42) (mean ± SD)	30.8 ± 6.3	30.4 ± 5.8
Pain (numerical scale) (0–10) (mean ± SD)	6.0 ± 1.8	6.4 ± 1.5
FIRST (0–6) (mean ± SD)	5.4 ± 0.8	5.6 ± 0.8
FIQ (0–100) (mean ± SD)	59.7 ± 10.7	62.3 ± 14.5
BPI Pain severity (0–10) (mean ± SD)	5.4 ± 1.2	5.7 ± 1.2
BPI Pain interference (0–10) (mean ± SD)	5.8 ± 1.7	5.9 ± 2.1
BPI Pain Experience (0–10) (mean ± SD)	5.6 ± 1.2	5.8 ± 1.3
PSQI Global score (0–21) (mean ± SD)	11.5 ± 3.2	13.8 ± 3.2
PSQI Subjective sleep quality (0–3) (mean ± SD)	2.1 ± 0.7	2.2 ± 0.7
PSQI Sleep latency (0–3) (mean ± SD)	2.1 ± 0.9	2.4 ± 0.8
PSQI Sleep duration (0–3) (mean ± SD)	1.2 ± 0.9	1.8 ± 0.9
PSQI Sleep efficiency (0–3) (mean ± SD)	1.3 ± 1.2	2.0 ± 1.1
PSQI Sleep disturbance (0–3) (mean ± SD)	2.2 ± 0.6	2.1 ± 0.5
PSQI Use of sleep medication (0–3) (mean ± SD)	1.2 ± 1.4	1.5 ± 1.5
PSQI Daytime dysfunction (0–3) (mean ± SD)	1.5 ± 0.8	1.9 ± 0.8
SF12-Mental score (0–100) (mean ± SD)	31.6 ± 6.2	33.0 ± 9.3
SF12-Physical score (0–100) (mean ± SD)	30.9 ± 5.8	30.7 ± 5.7
FSS (9–63) (mean ± SD)	51.9 ± 10.3	50.0 ± 12.0
PCS Total (0–52) (mean ± SD)	29.7 ± 10.5	28.9 ± 13.1
PCS Rumination (0–16) (mean ± SD)	9.3 ± 4.1	8.6 ± 4.9
PCS Magnification (0–12) (mean ± SD)	5.3 ± 2.8	6.1 ± 3.5
PCS Helplessness (0–24) (mean ± SD)	15.2 ± 4.9	14.2 ± 6.1
Precariousness (EPICES), (10–75) (mean ± SD)	26.9 ± 21.0	24.0 ± 19.8
Serum Mg (mmol/L) (mean ± SD)	0.92 ± 0.08	0.91 ± 0.08
Erythrocyte Mg (mmol/L) (mean ± SD)	2.86 ± 0.32	2.97 ± 0.31